Atovaquone-Proguanil

Amendment / Modification

This modification (P00002) updates the contract SPE2D2-24-D-0005 by implementing changes based on DoD Class Deviations 2025-00003 and 2025-00004. These deviations relate to "Restoring Merit-Based Opportunity in Federal Contracts" and "Revocation of Executive Order on Sustainability."

Key changes include:

• Deletion of several solicitation provisions and contract clauses related to equal opportunity, affirmative action, and environmental management systems.

• Revision of the "Waste Reduction Program" clause (52.223-10) to align with Deviation 2025-00004, redefining terms and emphasizing compliance with federal, state, and local requirements, including the Resource Conservation and Recovery Act.

• Revision of the "Sustainable Products and Services" clause (52.223-23) to align with Deviation 2025-00004. This revision clarifies definitions for biobased products, recovered materials, and sustainable products/services, referencing EPA's Comprehensive Procurement Guidelines, ENERGY STAR, FEMP, and USDA's BioPreferred program. It also outlines contractor requirements for ensuring sustainable products and services are used.

• Substitution of various paragraphs within other clauses, including "Annual Representations and Certifications" (52.204-8), "Offeror Representations and Certifications-Commercial Products and Commercial Services" (52.212-3), and "Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Products and Commercial Services" (52.212-5), to reflect the new deviations. Many of these substitutions involve reserving paragraphs, indicating a change in applicability or removal of previous requirements.

• Solicitation provisions and contract clauses related to equal opportunity, affirmative action, environmental management systems, waste reduction, and sustainable products/services.

• Specific paragraphs within FAR clauses 52.204-8, 52.212-3, 52.212-5, 52.213-4, 52.222-9, and 52.244-6.

• The modification does not appear to change proposal deadlines or submission rules, as it primarily affects existing contract terms and clauses. However, contractors must notify the contracting officer if they do not agree with the modification or are not in compliance, as continued performance will be considered acceptance.

Amendment / Modification

• Option 2 of the contract SPE2D2-24-D-0005 is exercised.

• The period of performance for Option 2 is effective from April 04, 2026, through April 03, 2027.

• This modification exercises Option 2 as per FAR 52.217-9.

• All other terms and conditions of the original contract remain unchanged. No impact on proposal submission deadlines or requirements as this is an option exercise.

Amendment / Modification

• Option 1 is exercised, extending the period of performance from April 4, 2025, through April 3, 2026.

• The unit price for NDC 51407-0869-24 (Atovaquone-Proguanil 250MG-100MG Tablet 24 Count) has been changed from $35.00 to $33.27.

• Option 1 period of performance.

• Unit price for a specific NDC.

• This modification exercises an option and adjusts pricing. It does not appear to alter proposal submission deadlines or requirements for any outstanding solicitation.

Solicitation / RFP / RFQ

This document is a solicitation/contract award for Atovaquone-Proguanil 250MG-100MG tablets, in both 24-count and 100-count bottles. The Defense Logistics Agency (DLA) is the issuing agency.

• Procurement of Atovaquone-Proguanil 250MG-100MG tablets in two package sizes: 24-count and 100-count.

• The contract includes a Base Year and four Option Years for each item.

• The products will be manufactured by Mylan Laboratories, LTD in India and packaged/labeled by Mylan Laboratories and Golden State Medical Supply Inc.

• Contract Number: SPE2D2-24-D-0005

• Award/Effective Date: April 4, 2024

• Estimated Total Award Amount: $20,495,935.00 for 5 years, or $4,099,187.00 for 1 year.

• Contract Type: Likely a requirements contract or similar, as quantities are estimates.

• This document reflects an award based on a previous solicitation (SPE2D2-23-R-0013).

• The award incorporates the offeror's submitted offer, response to negotiations, and final proposal revision.

• The acquisition is set aside for Small Business.

• NAICS Code: 325412

• Size Standard: 1300 employees.

• The document lists numerous Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses incorporated by reference.

• Appendix A lists current Pharmaceutical Prime Vendors as of the solicitation date.